Document Classification

Section Type: RESULTS

Text: Among 45 patients with post-baseline ratings, olanzapine (9. 05. 8 mg/day, n = 23) compared to placebo (n = 22) tended to yield greater Clinical Global Impressions-Bipolar Version-Overall Severity of Illness (-1. 40. 9 versus -0. 81. 1, p = 0. 08) and Hamilton Anxiety Scale (-7. 96. 3 versus -3. 86. 1, p = 0. 07) improvements, and YMRS/HDRS remission rate (47. 8 % versus 22. 7 %, p = 0. 08), but significantly increased median weight (+2 versus -1 lbs, p = 0. 001), and rates of excessive appetite (54. 2 % versus 22. 7 %, p = 0. 04) and tremor (50. 0 % versus 9. 1 % p = 0. 004).